MYC and cancer: Besides, we delineated the genomic features of WDHD1 at the pan-cancer level, including expression and mutations, and explored for the first time the relationship between its paclitaxel and rapamycin resistance, tumor heterogeneity, RNA methylation modification, MYC, and E2F pathways.